Can I read A Study On Pirfenidone Versus Nintedanib in Patients With Idiopathic Pulmonary Fibrosis in A Tertiary Care Hospital: A Cross Sectional Study on EtoBox?

A Study On Pirfenidone Versus Nintedanib in Patients With Idiopathic Pulmonary Fibrosis in A Tertiary Care Hospital: A Cross Sectional Study by IJAR JOURNAL is a document available to read on EtoBox.

What is A Study On Pirfenidone Versus Nintedanib in Patients With Idiopathic Pulmonary Fibrosis in A Tertiary Care Hospital: A Cross Sectional Study about?

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic condition with a poor prognosis and have an average life expectancy of 3-4 years. Two antifibrotic treatments have been approved to treat IPF: nintedanib and pirfenidone. These medications lower the decline in lung function and lower the risk of acute respiratory deterioration, which is linked with a high morbidity and death.Individual clinical trials have not been powered to demonstrate mortality decreases, however analysis of pooled

Author

IJAR JOURNAL

Language

EN